Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hemax is an oral nutritional supplement and therapeutic mineral product developed by Pronova Corp, specifically designed to treat or prevent iron deficiency and iron-deficiency anemia while mitigating the common side effect of constipation. The formulation features carbonyl iron, a highly pure form of elemental iron that is naturally regulated by the body during absorption, making it generally better tolerated and less toxic than traditional ferrous salts. To counteract the gastrointestinal distress and constipation typically associated with high-dose iron supplementation, Hemax includes docusate sodium, a surfactant that acts as a stool softener. The supplement is further enriched with Vitamin C (ascorbic acid) to enhance iron absorption, as well as essential B-vitamins including Vitamin B12 and folic acid (often provided as L-methylfolate) and minerals like copper and biotin, which serve as vital cofactors for erythropoiesis and red blood cell maturation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Hemax.